Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Objectives We aimed to compare COVID-19 outcomes in the Omicron-driven fourth wave with prior waves in the Western Cape, the contribution of undiagnosed prior...

  • NYT covered Kaiser CA study: S. Africa study here Risk of severe disease Omicron wave compared to prior 3; adjusted for vax/prior infection. Risk reduced by prior immunity; Vax protected a lot (hazard ratio 0.26); ~25% inherently less virulent than delta https://t.co/U08uX2EqfM - view on twitter

Original Article from The New England Journal of Medicine — Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in...

Dr. Anthony Fauci this week addressed Covaxin, a COVID-19 vaccine made in India that has not been approved in the U.S. but is finding...

This study delineates the transmission dynamics of coronavirus disease 2019 (COVID-19) and evaluates the transmission risk at different exposure window periods before and after...

Mashup Score:39

Bloomberg

European Union regulators warned that frequent Covid-19 booster shots could adversely affect the immune response and may not be...

  • Boosters in typical ID given usually given for those at risk of severe breakthrough, seems to have been given to try to decrease transmission for others (antibodies likely come down after 10 weeks), 4th doses being given for immunocompromised, not all https://t.co/IFZcYSel7h - view on twitter

These charts show why, despite breakthrough infections and milder symptoms overall, the Omicron variant is a major risk to the...

  • Statistics countrywide on how mainly unvaccinated are ones with severe covid. In ID, an asymptomatic or mildly symptomatic “breakthrough” not usually considered a vaccine failure but severe breakthrough is -so need treatments (and boosters) https://t.co/jkdvJL13Iy - view on twitter

The arrival of Omicron, the most transmissible COVID-19 variant to date, underscores the tremendous need for updated COVID-19 policy in the...

The stunning Covid vaccines manufactured by Pfizer-BioNTech and Moderna drew upon long-buried discoveries made in the hopes of ending past...

Antibodies aren’t the whole...

This Viewpoint provides a summary of currently available therapeutics for nonhospitalized patients with COVID-19 in the setting of the Omicron variant including principles for...